UNASSIGNED: Objectives. This open-label study assessed the efficacy and safety of exclusive night-time administration of transdermal @entity26742 in @entity1 with nocturnal and early morning @entity1726 symptoms. Methods. @entity1 with @entity1726 and nocturnal and early morning symptoms received transdermal @entity26742 patches (2-16   mg/24   h) applied in the evening and removed in the morning for 3 months. Sleep disturbance was assessed with modified @entity191 Sleep Scale ( @entity26874 ). Other outcomes included a @entity158 visual analogue scale (VAS) and short-form @entity191 Questionnaire (PDQ-8) for quality of life. Results. 74 @entity1 completed treatment in this study. At the end of treatment, @entity26874 total score had improved by mean 10.9 points from baseline (p < 0.001). All three @entity26874 domain scores (sleep disturbances, nocturnal motor symptoms, and nocturnal symptoms) were also significantly improved by 41%, 56%, and 48%, respectively (p < 0.001). VAS- @entity158 score decreased from 3.2 to 2.3 (p < 0.001). PDQ-8 score decreased from 23.8 to 18.1 (p < 0.001). The most frequently reported adverse events included @entity390 (9%), @entity148 (4%), and @entity1296 (4%). Conclusions. Night-time administration of transdermal @entity26742 is an effective and well tolerated treatment for nocturnal symptoms in @entity1 with @entity1726 .

Effects of Night-Time Use of @entity26742 on Nocturnal Symptoms in XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity26742 :: ('MESH:C047508', 'Chemical') :: ['rotigotine'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity191 :: ('MESH:D010300', 'Disease') :: ["Parkinson's Disease"] @entity1726 :: ('OMIM:168600', 'Disease') :: ['PD'] @entity26874 :: ('57107', 'Gene') :: ['PDSS-2'] @entity148 :: ('MESH:D001008', 'Disease') :: ['anxiety'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']
@entity191 :: (MESH:D010300,Disease) :: ['Parkinson's Disease']
